CD8A and neoplasm: Based on encouraging evidence (albeit from small studies) showing measurable WT1-specific anti-tumor CD8+ T cell responses [94,95], a WT1 peptide vaccine using Montanide and GM-CSF as adjuvants is currently being explored in a phase I study in patients with recurrent OC who are in second or later remission.